Showing 2951-2960 of 5685 results for "".
- World Council of Optometry and Alcon Video Series Summarizes TFOS DEWS IIIhttps://modernod.com/news/world-council-of-optometry-and-alcon-video-series-summarizes-tfos-dews-iii/2486845/World Council of Optometry (WCO) and Alcon have released a series of three videos to help eye care professionals (ECPs) around the world understand and apply recommendations from the r
- Haag-Streit USA, Marco Lombart Sign Exclusive US Distribution Deal for Diagnostic Platformshttps://modernod.com/news/haag-streit-usa-marco-lombart-sign-exclusive-us-distribution-deal-for-diagnostic-platforms/2486763/Haag-Streit USA and Marco Lombart have entered into an exclusive distribution agreement for the Lenstar 900 optical biometer and the Octopus 600 and Octopus 900 perimeters in the United States. Under the agreement, Marco Lomb
- Revenio Group to Acquire Visionix in 290 Million Euro Dealhttps://modernod.com/news/revenio-group-to-acquire-visionix-in-290-million-euro-deal/2486649/Revenio Group has signed an agreement to acquire the entire share capital of France-based LT International SAS, the parent company of the Visionix International group, in a transaction valued at €290 million ($342 million). T
- China Approves World’s First Implantable Device for Congenital Nystagmus Treatmenthttps://modernod.com/news/china-approves-worlds-first-implantable-device-for-congenital-nystagmus-treatment/2486098/
- International Study Shows Large Language Models Now Excel on Ophthalmology Specialty Exams but Risks Remainhttps://modernod.com/news/international-study-shows-large-language-models-now-excel-on-ophthalmology-specialty-exams-but-risks-remain/2485591/A new study published this week in Eye reveals that the latest generation of large language models (LLMs) have made dramatic gains in performance on specialty o
- New Study Shows Foundation AI Models Closing the Gap With Doctors—But Multimodal Challenges Remainhttps://modernod.com/news/new-study-shows-foundation-ai-models-closing-the-gap-with-doctorsbut-multimodal-challenges-remain/2485340/A new cross-sectional study published in JAMA Ophthalmology examines how current foundation artificial intelligence (AI) models perform on ophthalmology exam questions compared with human physicians. The data reveal notable progress on text-based tasks but
- Everest Medicines Expands into Ophthalmology with Licensing Agreement for Retinal Disease Candidate in Asiahttps://modernod.com/news/everest-medicines-expands-into-ophthalmology-with-licensing-agreement-for-retinal-disease-candidate-in-asia/2484302/Everest Medicines announced it has entered into an exclusive licensing agreement with Visara, a subsidiary of NovaBridge Biosciences to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countri
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie